SeaStar Medical reaches interim enrollment target for NEUTRALIZE-AKI

SeaStar Medical (ICU) announced that it has successfully reached the halfway point in the NEUTRALIZE-AKI pivotal clinical trial, enabling a per protocol prespecified interim analysis by the trial’s independent Data Safety Monitoring Review Board, DSMB. SeaStar Medical anticipates the DSMB will report its findings to the company in the third quarter of 2025. “We are very pleased to reach this important enrollment milestone in the NEUTRALIZE-AKI pivotal trial,” stated Eric Schlorff, CEO of SeaStar Medical. “Kevin and his team have done an incredible job activating nationally recognized clinical trial sites, such as Cleveland Clinic, Mayo Clinic, and Stanford Medical Center. These and our other clinical sites are clearly aware of the high unmet need of these patients, and we are grateful for their active participation in the trial.”